LXR-623

CAT:

804-HY-10629-06

Size:

200 mg

Price:

Ask

For price, please contact [email protected]

CAS Number: 875787-07-8
UNSPSC Description: LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
Target Antigen: LXR
Type: Reference compound
Related Pathways: Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
Applications: Cancer-programmed cell death
Field of Research: Metabolic Disease; Cancer
Assay Protocol: https://www.medchemexpress.com/LXR-623.html
Purity: 99.88
Solubility: DMSO : ≥ 47 mg/mL
Smiles: ClC1=C(CN2N=C(C(C(F)(F)F)=CC=C3)C3=C2C4=CC=C(F)C=C4)C=CC(F)=C1
Molecular Weight: 422.78
References & Citations: [1]Villa GR, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14;30(5):683-693.|[2]Giannarelli C, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012 Jan;33(2):264-73.|[3]Quinet EM, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res. 2009 Dec;50(12):2358-70.|[4]DiBlasio-Smith EA, et al. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. J Transl Med. 2008 Oct 16;6:59.
Shipping Conditions: Room Temperature
Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
Clinical Information: Phase 1